Edaravone Protects Trophoblast Cells From Hypoxic Injury in Preeclampsia: Inhibition of the PI3K/AKT Pathway as a Promising Therapeutic Approach
Immunity, Inflammation and Disease · 2024
DOI: 10.1002/iid3.70097 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunity, Inflammation and Disease, 2024. Verfasst von Xin Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, General Hospital of Northern Theater Command, Shenyang, Liaoning, China. Hauptthemen laut MEDLINE: Pre-Eclampsia, Trophoblasts, Proto-Oncogene Proteins c-akt, Edaravone. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This work is sponsored by the Medical Science and Technology Research Project of Henan Province, Liaoning Province Minsheng Science and Technology Plan Joint P….
Abstract (Originalsprache)
Objective
Preeclampsia (PE) is a multifaceted medical condition that manifests during pregnancy, characterized by hypertension and damage to multiple organs. In PE, the placenta's impaired functionality leads to continuous hypoxia in placental tissues, which is considered the primary cause of the condition. Inhibition of hypoxia‐induced injury in trophoblast cells presents a potential therapeutic strategy for PE. Edaravone (EDA) is a potent antioxidant with proven efficacy against various diseases and injuries, yet its impact on PE requires further exploration.
Methods
Placenta tissues from pregnant women, with or without PE, were collected, and levels of hypoxia‐inducible factor (HIF‐1α), P‐AKT, AKT, and PI3K proteins were analyzed using Western blotting. An in vitro anoxia model was established by treating the human trophoblast cell line HTR‐8/SVneo with cobalt chloride (CoCl 2 ). Standard techniques were employed to measure proliferation, apoptosis, and reactive oxygen species (ROS) production rates in the anoxic cells, with and without EDA treatment.
Results
HIF‐1α, P‐AKT, AKT, and PI3K protein levels were significantly elevated in the placenta of the PE group compared with the control group. EDA mitigated the CoCl 2 ‐induced decrease in HTR‐8/SVneo cell viability and reduced apoptosis and ROS production. Furthermore, EDA counteracted the activation of the PI3K/AKT pathway in CoCl 2 ‐treated trophoblasts.
Conclusion
EDA protected trophoblasts against hypoxic injury by inhibiting the PI3K/AKT pathway, suggesting that it may serve as a promising therapeutic option for PE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, General Hospital of Northern Theater Command, Shenyang, Liaoning, China.
- Department of Blood Transfusion, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
- Department of General Practice Department, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
- College of Medicine and Biological Information Engineering, Northeastern University, Shenyang, Liaoning, China.
ORCID-Profile: Zhaomin Yao
Förderung
- This work is sponsored by the Medical Science and Technology Research Project of Henan Province, Liaoning Province Minsheng Science and Technology Plan Joint P…
Zitieren
APA
Liu, X., Wan, J., Wei, M., Tong, Y., & Yao, Z. (2024). Edaravone Protects Trophoblast Cells From Hypoxic Injury in Preeclampsia: Inhibition of the PI3K/AKT Pathway as a Promising Therapeutic Approach. Immunity, Inflammation and Disease. https://doi.org/10.1002/iid3.70097
Vancouver
Liu X, Wan J, Wei M, Tong Y, Yao Z. Edaravone Protects Trophoblast Cells From Hypoxic Injury in Preeclampsia: Inhibition of the PI3K/AKT Pathway as a Promising Therapeutic Approach. Immunity, Inflammation and Disease. 2024. doi:10.1002/iid3.70097
BibTeX
@article{Liu2024,
author = {Liu, Xin and Wan, Jun and Wei, Ming and Tong, Yanan and Yao, Zhaomin},
title = {Edaravone Protects Trophoblast Cells From Hypoxic Injury in Preeclampsia: Inhibition of the PI3K/AKT Pathway as a Promising Therapeutic Approach},
journal = {Immunity, Inflammation and Disease},
year = {2024},
doi = {10.1002/iid3.70097}
}
EUVIMED